tirzepatide head to head semaglutide outperforms in NEJM trial for weight loss | Yousaf A posted on the topic Switching between weight-loss medications -

If any of these markers are missing, discuss with your provider or pharmacy about potential formulation issues

Hirayama F, Lee AH, Oura A, Mori M, Hiramatsu N, Taniguchi H

The treatment arm achieved an 18 percent mean reduction in visceral adipose tissue versus a small increase in placebo, with statistically significant improvements in triglycerides (minus 50 mg/dL), total cholesterol, and patient-reported body image

We have seen a lot of inflammation We have medications to bring those inflammatory markers down

Who Is Eligible to File an Ozempic Lawsuit in Houston

The regulatory context for compounded GLP-1 in 2026 FDA removed semaglutide from its drug shortage list in early 2025, which changed the primary legal basis that had allowed widespread compounding of semaglutide under shortage-exemption rules